Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigimadlin long-term safety extension study in patients with solid tumors
CTR20253950Phase 2Active
- Sponsor
- 不适用/ 勃林格殷格翰(中国)投资有限公司
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brigimadlin in Nonhematologic neoplasms, sponsored by 不适用/ 勃林格殷格翰(中国)投资有限公司. Started Nov 2025; status: active.
02
Drugs
brigimadlin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20253950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253950.